{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transformed+Lymphoma&page=8", "query": { "condition": "Transformed Lymphoma", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 433, "total_pages": 44, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transformed+Lymphoma&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Transformed+Lymphoma&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-22T23:16:20.832Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01233921", "title": "Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities", "Adult Acute Myeloid Leukemia With Del(5q)", "Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)", "Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)", "Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Chronic Eosinophilic Leukemia", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Graft Versus Host Disease", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncontiguous Stage II Adult Burkitt Lymphoma", "Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma", "Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma", "Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma", "Noncontiguous Stage II Adult Lymphoblastic Lymphoma", "Noncontiguous Stage II Grade 1 Follicular Lymphoma", "Noncontiguous Stage II Grade 2 Follicular Lymphoma", "Noncontiguous Stage II Grade 3 Follicular Lymphoma", "Noncontiguous Stage II Mantle Cell Lymphoma", "Noncontiguous Stage II Marginal Zone Lymphoma", "Noncontiguous Stage II Small Lymphocytic Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Primary Myelofibrosis", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Splenic Marginal Zone Lymphoma", "Stage I Multiple Myeloma", "Stage II Multiple Myeloma", "Stage III Adult Burkitt Lymphoma", "Stage III Adult Diffuse Large Cell Lymphoma", "Stage III Adult Diffuse Mixed Cell Lymphoma", "Stage III Adult Diffuse Small Cleaved Cell Lymphoma", "Stage III Adult Hodgkin Lymphoma", "Stage III Adult Immunoblastic Large Cell Lymphoma", "Stage III Adult Lymphoblastic Lymphoma", "Stage III Chronic Lymphocytic Leukemia", "Stage III Grade 1 Follicular Lymphoma", "Stage III Grade 2 Follicular Lymphoma", "Stage III Grade 3 Follicular Lymphoma", "Stage III Mantle Cell Lymphoma", "Stage III Marginal Zone Lymphoma", "Stage III Multiple Myeloma", "Stage III Small Lymphocytic Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "palifermin", "type": "BIOLOGICAL" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "Martin, Paul", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6, "start_date": "2010-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2014-04-02", "last_synced_at": "2026-10-22T23:16:20.832Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01233921" }, { "nct_id": "NCT00025415", "title": "Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Accelerated Phase Chronic Myelogenous Leukemia", "Acute Undifferentiated Leukemia", "AIDS-related Peripheral/Systemic Lymphoma", "AIDS-related Primary CNS Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Blastic Phase Chronic Myelogenous Leukemia", "Childhood Myelodysplastic Syndromes", "Chronic Eosinophilic Leukemia", "Chronic Myelogenous Leukemia, BCR-ABL1 Positive", "Chronic Myelomonocytic Leukemia", "Chronic Neutrophilic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "de Novo Myelodysplastic Syndromes", "Essential Thrombocythemia", "Extramedullary Plasmacytoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Gastrointestinal Stromal Tumor", "Intraocular Lymphoma", "Isolated Plasmacytoma of Bone", "Meningeal Chronic Myelogenous Leukemia", "Monoclonal Gammopathy of Undetermined Significance", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Polycythemia Vera", "Previously Treated Myelodysplastic Syndromes", "Primary Central Nervous System Non-Hodgkin Lymphoma", "Primary Myelofibrosis", "Primary Systemic Amyloidosis", "Progressive Hairy Cell Leukemia, Initial Treatment", "Prolymphocytic Leukemia", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Acute Myeloid Leukemia", "Secondary Myelodysplastic Syndromes", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Stage IV Adult Burkitt Lymphoma", "Stage IV Adult Diffuse Large Cell Lymphoma", "Stage IV Adult Diffuse Mixed Cell Lymphoma", "Stage IV Adult Diffuse Small Cleaved Cell Lymphoma", "Stage IV Adult Hodgkin Lymphoma", "Stage IV Adult Immunoblastic Large Cell Lymphoma", "Stage IV Adult Lymphoblastic Lymphoma", "Stage IV Adult T-cell Leukemia/Lymphoma", "Stage IV Chronic Lymphocytic Leukemia", "Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma", "Stage IV Grade 1 Follicular Lymphoma", "Stage IV Grade 2 Follicular Lymphoma", "Stage IV Grade 3 Follicular Lymphoma", "Stage IV Mantle Cell Lymphoma", "Stage IV Marginal Zone Lymphoma", "Stage IV Mycosis Fungoides/Sezary Syndrome", "Stage IV Small Lymphocytic Lymphoma", "T-cell Large Granular Lymphocyte Leukemia", "Unspecified Adult Solid Tumor, Protocol Specific", "Untreated Adult Acute Lymphoblastic Leukemia", "Untreated Adult Acute Myeloid Leukemia", "Untreated Hairy Cell Leukemia", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "imatinib mesylate", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": null, "sex": "ALL", "summary": "15 Years and older" }, "enrollment_count": 60, "start_date": "2001-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-02-07", "last_synced_at": "2026-10-22T23:16:20.832Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00025415" }, { "nct_id": "NCT00571493", "title": "VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-hodgkin's Lymphoma", "Mantle Cell Lymphoma" ], "interventions": [ { "name": "Bortezomib", "type": "DRUG" }, { "name": "BEAM (carmustine (BCNU), etoposide, cytarabine, melphalan)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Nebraska", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "19 Years", "maximum_age": null, "sex": "ALL", "summary": "19 Years and older" }, "enrollment_count": 42, "start_date": "2006-04-14", "completion_date": "2014-11-01", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-22T23:16:20.832Z", "location_count": 1, "location_summary": "Omaha, Nebraska", "locations": [ { "city": "Omaha", "state": "Nebraska" } ], "official_url": "https://clinicaltrials.gov/study/NCT00571493" }, { "nct_id": "NCT01499147", "title": "Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Leukemia", "Chronic Myelogenous Leukemia", "Malignant Lymphoma", "Hodgkin's Disease", "Multiple Myeloma", "Lymphocytic Leukemia", "Myeloproliferative Disorder", "Polycythemia Vera", "Myelofibrosis", "Aplastic Anemia" ], "interventions": [ { "name": "fludarabine/busulfan", "type": "DRUG" }, { "name": "fludarabine/ melphalan", "type": "DRUG" }, { "name": "ATG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Illinois at Chicago", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "10 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "10 Years to 65 Years" }, "enrollment_count": 100, "start_date": "2000-02", "completion_date": "2013-05", "has_results": true, "last_update_posted_date": "2018-11-08", "last_synced_at": "2026-10-22T23:16:20.832Z", "location_count": 1, "location_summary": "Chicago, Illinois", "locations": [ { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT01499147" }, { "nct_id": "NCT00372905", "title": "Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "rituximab", "type": "DRUG" }, { "name": "bortezomib", "type": "DRUG" }, { "name": "Ibritumomab tiuxetan", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2007-07-24", "completion_date": "2013-07-08", "has_results": true, "last_update_posted_date": "2019-09-04", "last_synced_at": "2026-10-22T23:16:20.832Z", "location_count": 2, "location_summary": "Atlanta, Georgia • Chicago, Illinois", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00372905" }, { "nct_id": "NCT00003294", "title": "Chemotherapy Given With Amifostine and Filgrastim in Treating Patients With Recurrent or Metastatic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "amifostine trihydrate", "type": "DRUG" }, { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 24, "start_date": "1997-05", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2011-03-07", "last_synced_at": "2026-10-22T23:16:20.832Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003294" }, { "nct_id": "NCT02924402", "title": "Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-cell Non-Hodgkins Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "XmAb13676", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Xencor, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 154, "start_date": "2016-10", "completion_date": "2024-04", "has_results": false, "last_update_posted_date": "2024-11-13", "last_synced_at": "2026-10-22T23:16:20.832Z", "location_count": 10, "location_summary": "La Jolla, California • Jacksonville, Florida • Atlanta, Georgia + 7 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02924402" }, { "nct_id": "NCT00055653", "title": "Donor Umbilical Cord Blood Transplantation in Treating Patients With Leukemia, Lymphoma, or Nonmalignant Hematologic Disorders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic-Myeloproliferative Diseases" ], "interventions": [ { "name": "anti-thymocyte globulin", "type": "BIOLOGICAL" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "busulfan", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cyclosporine", "type": "DRUG" }, { "name": "fludarabine phosphate", "type": "DRUG" }, { "name": "melphalan", "type": "DRUG" }, { "name": "methylprednisolone", "type": "DRUG" }, { "name": "umbilical cord blood transplantation", "type": "PROCEDURE" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "PROCEDURE", "RADIATION" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "17 Years", "sex": "ALL", "summary": "Up to 17 Years" }, "enrollment_count": null, "start_date": "2003-01", "completion_date": "2005-09", "has_results": false, "last_update_posted_date": "2011-03-07", "last_synced_at": "2026-10-22T23:16:20.832Z", "location_count": 25, "location_summary": "Duarte, California • Los Angeles, California • Orange, California + 20 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055653" }, { "nct_id": "NCT04771572", "title": "Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Non Hodgkin Lymphoma", "Richter Transformation", "Multiple Myeloma", "T-cell-prolymphocytic Leukemia", "Acute Myeloid Leukemia", "Acute Lymphocytic Leukemia", "Myeodysplastic Syndrome", "Myelodysplastic/Myeloproliferative Neoplasm", "Myelofibrosis", "Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Chronic Myelomonocytic Leukemia-2", "Myelodysplastic Neoplasm in Blast Phase" ], "interventions": [ { "name": "LP-118", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Newave Pharmaceutical Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "13 Years", "maximum_age": null, "sex": "ALL", "summary": "13 Years and older" }, "enrollment_count": 100, "start_date": "2022-05-08", "completion_date": "2027-12-31", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-22T23:16:20.832Z", "location_count": 8, "location_summary": "Chicago, Illinois • Boston, Massachusetts • Chapel Hill, North Carolina + 4 more", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Chapel Hill", "state": "North Carolina" }, { "city": "Cincinnati", "state": "Ohio" }, { "city": "Cincinnati", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT04771572" }, { "nct_id": "NCT05202782", "title": "Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation", "EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "High Grade B-Cell Lymphoma, Not Otherwise Specified", "Large B-Cell Lymphoma With IRF4 Rearrangement", "Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type", "Recurrent Aggressive B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Recurrent Intravascular Large B-Cell Lymphoma", "Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Recurrent T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Recurrent Transformed B-Cell Non-Hodgkin Lymphoma", "Refractory Aggressive B-Cell Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified", "Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Refractory Intravascular Large B-Cell Lymphoma", "Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma", "Refractory T-Cell/Histiocyte-Rich Large B-Cell Lymphoma", "Refractory Transformed B-Cell Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Chimeric Antigen Receptor T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Zanubrutinib", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "Northwestern University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 24, "start_date": "2022-03-21", "completion_date": "2029-10-09", "has_results": false, "last_update_posted_date": "2024-10-16", "last_synced_at": "2026-10-22T23:16:20.832Z", "location_count": 2, "location_summary": "Chicago, Illinois • Milwaukee, Wisconsin", "locations": [ { "city": "Chicago", "state": "Illinois" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05202782" } ] }